News brief­ing: Gilead sub­mits fil­go­tinib to Eu­ro­pean reg­u­la­tors for UC; GW Phar­ma­ceu­ti­cals launch­es PhI­II tri­al for MS can­di­date made with cannabis ex­tracts

Gilead’s fil­go­tinib is get­ting a chance at a new in­di­ca­tion in Eu­rope af­ter the US reg­u­la­tors hand­ed down a CRL a few months ago.

The com­pa­ny an­nounced Mon­day af­ter­noon that the EMA is tak­ing up a sec­ond re­view for the JAK1 in­hibitor, this time in ul­cer­a­tive col­i­tis. Mar­ket­ed as Jy­s­e­le­ca on the con­ti­nent, fil­go­tinib has al­ready been ap­proved for adults with mod­er­ate to se­vere rheuma­toid arthri­tis who are re­sis­tant to oth­er an­ti-rheumat­ic drugs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER